Skip to main content

Affymetrix s Q4 Revenues Increase 3.5 Percent, Beating Earlier Projection Cuts; Profits Tumble

NEW YORK, Jan. 27 (GenomeWeb News) - Affymetrix reported yesterday a 3.5-percent increase in revenues for the fourth quarter of 2005.


Total revenue for the fourth quarter inched up to $111.5 million from $107.7 million during the year-ago period.


Affymetrix's Q4 revenues were approximately $6 million dollars above its last projection of $105 million. The company had cut its fourth-quarter revenue projection twice since the fall of 2005, citing "growing pains" as it brought new products into potential markets.


Affy's fourth-quarter profit fell 8.2 percent to $24.8 million, or $0.35 per share, from $27.1 million, or $0.41 per share, during the fourth quarter of 2004.


R&D spending during the period decreased to $19.7 million from $20.5 million year-over-year.


As of Dec. 31, 2005, Affymetrix had $100 million in cash and cash equivalents.


For fiscal 2006, Affymetrix predicted product and product-related revenue of about $400 million, and total revenue of about $420 million.


For the first quarter of 2006, Affy projected product and product-related revenue of $87 million, and total revenue of about $91 million.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.